To the full analysis
Buyback calculator for Arbutus Biopharma
Arbutus Biopharma stock: key metrics
ABUSArbutus Biopharma had an operating margin of −192.1% and a return on invested capital (ROIC) of −20.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 54.5% | −12.4% | 132.9% |
| 2007 | 100.0% | 16.6% | −16.2% |
| 2008 | −37.4% | −113.6% | −121.6% |
| 2009 | −23.1% | −65.8% | −67.7% |
| 2010 | −3.6% | −58.6% | −58.1% |
| 2011 | −19.5% | −63.3% | −59.7% |
| 2012 | −27.8% | −91.6% | 211.2% |
| 2013 | −38.8% | −78.6% | −90.9% |
| 2014 | −158.0% | −220.0% | −258.7% |
| 2015 | −107.1% | −411.4% | −245.7% |
| 2016 | −3,986.7% | −32,773.3% | −25,606.7% |
| 2017 | −486.0% | −1,036.4% | −788.8% |
| 2018 | −881.4% | −1,522.0% | −967.8% |
| 2019 | −858.3% | −2,394.0% | −2,557.4% |
| 2020 | −586.7% | −836.1% | −922.0% |
| 2021 | 100.0% | −669.1% | −693.9% |
| 2022 | 100.0% | −167.8% | −178.0% |
| 2023 | 100.0% | −430.5% | −401.6% |
| 2024 | 100.0% | −1,236.7% | −1,133.0% |
| 2025 | 97.4% | −192.1% | −237.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 200.0% | no data | 200.0% |
| 2007 | −14.1% | 22.3% | −10.4% |
| 2008 | −30.6% | −30.5% | −27.7% |
| 2009 | −26.3% | −59.3% | −22.2% |
| 2010 | −100.0% | −40.9% | −59.1% |
| 2011 | −100.0% | −82.6% | −71.0% |
| 2012 | 73.2% | −46.9% | 56.9% |
| 2013 | −23.8% | −19.0% | −19.6% |
| 2014 | −44.1% | −32.0% | −32.8% |
| 2015 | −11.2% | −47.2% | −8.6% |
| 2016 | −100.0% | −80.3% | −100.0% |
| 2017 | −46.2% | −35.7% | −35.6% |
| 2018 | −28.5% | −98.7% | −25.1% |
| 2019 | −100.0% | −72.3% | −100.0% |
| 2020 | −62.5% | −40.5% | −46.5% |
| 2021 | −45.0% | −36.2% | −37.3% |
| 2022 | −50.8% | −29.0% | −35.5% |
| 2023 | −68.7% | −43.3% | −50.4% |
| 2024 | −71.8% | −50.6% | −53.1% |
| 2025 | −43.7% | −20.8% | −35.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 20 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.